Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world.

The Journal of Antimicrobial Chemotherapy
Fábio P SelleraNilton Lincopan

Abstract

The COVID-19 pandemic has increased relationships and interactions between human and companion animals, supported by widespread social distancing and isolation measures. Additionally, the COVID-19 pandemic has led to an exponential growth in antibiotic and biocide use worldwide, possibly inducing further pressure, contributing to the selection of antibiotic-resistant bacteria, including WHO critical priority pathogens. While data from global surveillance studies reveal a linear trend of increasing carbapenem resistance among Gram-negative pathogens from companion animals, the acquisition of carbapenemase-producing Enterobacterales through direct contact with colonized hosts and contaminated veterinary hospital environments has been documented. This article highlights the rapid spread of WHO critical priority carbapenemase-producing pathogens in companion animals, which is a One Health challenge for a post-pandemic world.

References

Aug 24, 2011·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Jul 9, 2013·The Journal of Antimicrobial Chemotherapy·Inka StolleChrista Ewers
Jan 9, 2014·The Journal of Antimicrobial Chemotherapy·Sam AbrahamDarren J Trott
Mar 1, 2014·The Journal of Antimicrobial Chemotherapy·Laurent PoirelPatrice Nordmann
Nov 29, 2016·International Journal of Antimicrobial Agents·Christa EwersSandra Scheufen
Feb 2, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-Y MadecL Poirel
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Apr 15, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R KöckA Jurke
May 19, 2018·Emerging Infectious Diseases·Miriam R FernandesNilton Lincopan
Jul 12, 2018·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Thomas GrönthalMerja Rantala
Oct 20, 2018·Journal of Global Antimicrobial Resistance·Sophie PeterhansKatrin Zurfluh
Nov 1, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Jun Sung HongSeok Hoon Jeong
Dec 24, 2018·Frontiers in Microbiology·Fabio GentiliniRenato Giulio Zanoni
Jan 6, 2019·Journal of Infection and Public Health·Fábio P Sellera, Nilton Lincopan
May 24, 2019·Journal of Veterinary Internal Medicine·Alison SmithMarieke H Rosenbaum
Oct 3, 2019·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Aurélien NiggVincent Perreten
Dec 11, 2019·The Journal of Antimicrobial Chemotherapy·Andrea EndimianiBarbara Willi
Jan 22, 2020·Emerging Infectious Diseases·Stephen D ColeShelley C Rankin
Apr 3, 2020·The Journal of Antimicrobial Chemotherapy·Guillaume LhermieLuca Guardabassi
Nov 21, 2020·The Journal of Hospital Infection·J Ruiz
Jan 9, 2021·The Journal of Antimicrobial Chemotherapy·Kalisvar MarimuthuTimothy Barkham
Mar 27, 2021·Journal of the American Animal Hospital Association·Sondra H LavigneShelley C Rankin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

JAMA : the Journal of the American Medical Association
R F Herndon
Journal of Advanced Nursing
J P Smith
© 2021 Meta ULC. All rights reserved